VISIBLE: Guselkumab (GUS) skin and scalp clearance in skin of color (SOC) participants (pts) by baseline (BL) inflammatory disease burden

被引:0
|
作者
Farberg, A. [1 ]
Radusky, R. [2 ]
Moore, A. [3 ,4 ]
Han, G. [5 ]
Vasquez, J. [6 ]
Choi, O. [6 ]
Alkousakis, T. [6 ]
Rowland, K. [6 ]
Chan, D. [6 ]
Jeyarajah, J. [7 ]
Merola, J. [8 ,9 ]
Gottlieb, A. [10 ]
Desai, S. [8 ,9 ,11 ]
机构
[1] Bare Dermatol, Aubrey, TX USA
[2] Dermatol Treatment & Res Ctr, Dallas, TX USA
[3] Baylor Univ, Med Ctr, Dallas, TX USA
[4] Arlington Res Ctr, Arlington, TX USA
[5] Northwell Hlth Phys Partners, New York, NY USA
[6] JSA, Horsham, PA USA
[7] Janssen R&D, Spring House, PA USA
[8] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX USA
[9] Univ Texas Southwestern Med Ctr, Plano, TX USA
[10] Icahn Sch Med Mt Sinai, New York, NY USA
[11] Innovat Dermatol, Plano, TX USA
关键词
D O I
暂无
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
LB988
引用
收藏
页码:S174 / S174
页数:1
相关论文
共 2 条
  • [1] VISIBLE cohort B: guselkumab demonstrates significant scalp clearance at Week 16 in participants with moderate-to-severe scalp psoriasis across all skin tones
    Alexis, Andrew
    McMichael, Amy
    Bhutani, Tina
    Rodriguez, Adrian O.
    Grimes, Pearl
    Kindred, Chesahna
    Yadav, Geeta
    Yeung, Jensen
    Choi, Olivia
    Alkousakis, Theodore
    Chan, Daphne
    Rowland, Katelyn
    Pawlikowski, Jeffrey
    Jeyarajah, Jenny
    Gao, Long-Long
    Park-Wyllie, Laura
    Desai, Seemal R.
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [2] Study design of a phase 3b, multicenter, randomized, double-blind, placebo-controlled trial of guselkumab (GUS) in patients with skin of color who have moderate to severe plaque and/or scalp psoriasis (VISIBLE)
    Alexis, A.
    Bhutani, T.
    McMichael, A. J.
    Choi, O.
    Chan, D.
    Rowland, K.
    Gao, L.
    Park-Wyllie, L.
    Rodriguez, A.
    Kindred, C.
    Desai, S.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2022, 142 (08) : S119 - S119